Shilpa Medicare Limited

SHILPAMED

INE790G01031

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:53 2024-07-12 am EDT			5-day change	1st Jan Change
659.6 ^INR	-1.01%		-0.07%	+99.62%

Jul. 10	Shilpa Medicare Arm's API Facility in Karnataka, India, Passes Brazilian Drug Regulator's Inspection	MT
Jul. 09	Shilpa Medicare to Receive Shares from Unit as Loan Payment	MT

Shilpa Medicare Limited Appoints Sushil Bajaj as CFO

November 14, 2017 at 05:23 am EST

Shilpa Medicare Limited announced that the Board of Directors in their meeting held on 13 November, 2017 have considered and appointed Mr. Sushil Bajaj, a member of the Institute of Company Secretaries of India as CFO, effective from November 13, 2017.

Latest news about Shilpa Medicare Limited

Shilpa Medicare Arm's API Facility in Karnataka, India, Passes Brazilian Drug Regulator's Inspection	Jul. 10	MT
Shilpa Medicare to Receive Shares from Unit as Loan Payment	Jul. 09	MT
Transcript : Shilpa Medicare Limited - Shareholder/Analyst Call	Jul. 08
Shilpa Medicare Shares Rally 16% as Client Reports Positive Clinical Trial Results	Jul. 05	MT
INDIA STOCKS-HDFC Bank drags Indian shares as rally to record highs takes pause	Jul. 05	RE
Unicycive Therapeutics, Inc. Enters into First Amendment to Manufacturing and Supply Agreement with Shilpa Medicare, Ltd	Jul. 02	CI
Shilpa Medicare Bio Analytical Unit Gets "No Action Indicated" Classification from US FDA	Jun. 25	MT
Transcript : Shilpa Medicare Limited, Q4 2024 Earnings Call, May 24, 2024	May. 24
Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	May. 23	CI
Shilpa Medicare Limited Announces Successful Completion of Early Clinical Development and Ongoing Phase 3 Clinical Trial of Its Newly Developed Drug "SML-007", for the Treatment of Non-Alalcoholic Fatty Liver Disease	May. 14	CI
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US	Apr. 18	MT
Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit	Apr. 17	MT
Shilpa Medicare Gets Board Nod to Launch QIP	Apr. 09	MT
Shilpa Medicare's Life Science Arm Names CEO	Mar. 28	MT
Shilpa Medicare's New Unit in Hyderabad, India Gets Zero Observations from US FDA	Mar. 01	MT
Shilpa Medicare Gets Approval to Market Smoking Cessation Drug in Europe	Feb. 26	MT
Transcript : Shilpa Medicare Limited, Q3 2024 Earnings Call, Feb 12, 2024	Feb. 12
Shilpa Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Shilpa Medicare Gets Germany's Marketing Approval for Rare Muscles Diseases Drug	Jan. 19	MT
Shilpa Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 10	CI
Shilpa Medicare Acquires US-Based Pilnova Pharma	Nov. 02	MT
Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal	23-10-11	CI
Shilpa Medicare Unit's API Manufacturing Plant Gets Clearance from Japanese Drug Regulator's Inspection	23-09-04	MT
Shilpa Medicare Gets UK Drug Regulator's Nod to Market Drug for Meniere's Syndrome Symptoms	23-09-04	MT
Shilpa Medicare Limited Receives Marketing Authorization from MHRA, UK, for Betahistine Dihydrochloride Orodispersible Films, 24 mg	23-09-01	CI

Chart Shilpa Medicare Limited

Duration

Period

More charts

Company Profile

Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.

Sector

Pharmaceuticals

Calendar

2024-08-11 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHILPA MEDICARE LIMITED	+99.62%	686M
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B

Other Pharmaceuticals